bluuebunny/crossref_metadata_2025 huggingface dataset:
Topological Edge State Ring Resonator for Mid-Infrared(MI) Refractive Indices Biosensor for detection of Brain Tumors
Authors: D Satyaraj , Mubarakali Azath , N. A. Natraj , S. Gopinath
Published: June 2024

The unique properties of light underlie the perspectives of quantum photonic technologies, optical interconnects, and a wide range of new sensors.Some of the most dangerous and deadly diseases are tumors, cancers, and brain lesions, which are expensive to detect and treat. Therefore, a low-cost and accurate method to diagnose them can prevent and treat the progress of this disease. In this work, we used the precise topological valley photonic crystal (TVPC) method for detection. TVPC is an important method for transmitting and controlling light in the optical device. The valley-spin locking in the topology state provides robust transfer and low propagation loss at the desired path.In order to design, by finding the edge band within the first bulk band gap of 146.4 THz–155.9 THz, the model and design of the topological ring resonator (TRS)were realized. We proposed a topological biosensorbyusing the hexagonal lattice air holes in the silicon slab with a compact size of 22.95 μm × 10 μm. the quality factor and sensitivity at best value are 2.905 × 104 and 9021 nm RIU−1 respectively. This design can be implemented on the Complementary Metal-Oxide-Semiconductor (CMOS) technology as a high-sensitivity optical device.
Table S1 from White Blood Cell Count, Neutrophil-to-Lymphocyte Ratio, and Incident Cancer in the UK Biobank
Authors: Song Minkyo , Graubard Barry I. , Loftfield Erikka , Rabkin Charles S. , Engels Eric A.
Published: June 2024

Detailed smoking status and total white blood cell counts, and neutrophil-to-lymphocyte ratios
Supplementary Table S2 from Projecting the Impact of Multi-Cancer Early Detection on Late-Stage Incidence Using Multi-State Disease Modeling
Authors: Lange Jane M. , Gogebakan Kemal Caglar , Gulati Roman , Etzioni Ruth
Published: June 2024

Supplementary Table S2: Targeted cancers in MCED trial and test sensitivities in clinically detected patients.
Supplementary Figure S2 from Hypertension and Risk of Endometrial Cancer: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2)
Authors: Habeshian Talar S. , Peeri Noah C. , De Vivo Immaculata , Schouten Leo J. , Shu Xiao-ou , Cote Michele L. , Bertrand Kimberly A. , Chen Yu , Clarke Megan A. , Clendenen Tess V. , Cook Linda S. , Costas Laura , Dal Maso Luigino , Freudenheim Jo L. , Friedenreich Christine M. , Gallagher Grace , Gierach Gretchen L. , Goodman Marc T. , Jordan Susan J. , La Vecchia Carlo , Lacey James V. , Levi Fabio , Liao Linda M. , Lipworth Loren , Lu Lingeng , Matias-Guiu Xavier , Moysich Kirsten B. , Mutter George L. , Na Renhua , Naduparambil Jeffin , Negri Eva , O'Connell Kelli , O'Mara Tracy A. , Onieva Hernández Irene , Palmer Julie R. , Parazzini Fabio , Patel Alpa V. , Penney Kathryn L. , Prizment Anna E. , Ricceri Fulvio , Risch Harvey A. , Sacerdote Carlotta , Sandin Sven , Stolzenberg-Solomon Rachael Z. , van den Brandt Piet A. , Webb Penelope M. , Wentzensen Nicolas , Wijayabahu Akemi T. , Wilkens Lynne R. , Xu Wanghong , Yu Herbert , Zeleniuch-Jacquotte Anne , Zheng Wei , Du Mengmeng , Setiawan Veronica Wendy
Published: June 2024

Figure S2 is a forest plot of the association between hypertension and endometrial cancer by study site. It displays the associations between hypertension and endometrial cancer for each study site included grouped by study type (case-control, cohort)
Supplementary Figure S3 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Authors: Collister Jennifer A. , Liu Xiaonan , Littlejohns Thomas J. , Cuzick Jack , Clifton Lei , Hunter David J.
Published: June 2024

Supplementary Figure S3: Schoenfeld residual plots from Cox model containing Tyrer-Cuzick model 10-year risk and PRSBC, in training data (N=101,121).
Data from Hypertension and Risk of Endometrial Cancer: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2)
Authors: Habeshian Talar S. , Peeri Noah C. , De Vivo Immaculata , Schouten Leo J. , Shu Xiao-ou , Cote Michele L. , Bertrand Kimberly A. , Chen Yu , Clarke Megan A. , Clendenen Tess V. , Cook Linda S. , Costas Laura , Dal Maso Luigino , Freudenheim Jo L. , Friedenreich Christine M. , Gallagher Grace , Gierach Gretchen L. , Goodman Marc T. , Jordan Susan J. , La Vecchia Carlo , Lacey James V. , Levi Fabio , Liao Linda M. , Lipworth Loren , Lu Lingeng , Matias-Guiu Xavier , Moysich Kirsten B. , Mutter George L. , Na Renhua , Naduparambil Jeffin , Negri Eva , O'Connell Kelli , O'Mara Tracy A. , Onieva Hernández Irene , Palmer Julie R. , Parazzini Fabio , Patel Alpa V. , Penney Kathryn L. , Prizment Anna E. , Ricceri Fulvio , Risch Harvey A. , Sacerdote Carlotta , Sandin Sven , Stolzenberg-Solomon Rachael Z. , van den Brandt Piet A. , Webb Penelope M. , Wentzensen Nicolas , Wijayabahu Akemi T. , Wilkens Lynne R. , Xu Wanghong , Yu Herbert , Zeleniuch-Jacquotte Anne , Zheng Wei , Du Mengmeng , Setiawan Veronica Wendy
Published: June 2024

AbstractBackground:
The incidence rates of endometrial cancer are increasing, which may partly be explained by the rising prevalence of obesity, an established risk factor for endometrial cancer. Hypertension, another component of metabolic syndrome, is also increasing in prevalence, and emerging evidence suggests that it may be associated with the development of certain cancers. The role of hypertension independent of other components of metabolic syndrome in the etiology of endometrial cancer remains unclear. In this study, we evaluated hypertension as an independent risk factor for endometrial cancer and whether this association is modified by other established risk factors.
Methods:
We included 15,631 endometrial cancer cases and 42,239 controls matched on age, race, and study-specific factors from 29 studies in the Epidemiology of Endometrial Cancer Consortium. We used multivariable unconditional logistic regression models to estimate ORs and 95% confidence intervals (CI) to evaluate the association between hypertension and endometrial cancer and whether this association differed by study design, race/ethnicity, body mass index, diabetes status, smoking status, or reproductive factors.
Results:
Hypertension was associated with an increased risk of endometrial cancer (OR, 1.14; 95% CI, 1.09–1.19). There was significant heterogeneity by study design (Phet < 0.01), with a stronger magnitude of association observed among case–control versus cohort studies. Stronger associations were also noted for pre-/perimenopausal women and never users of postmenopausal hormone therapy.
Conclusions:
Hypertension is associated with endometrial cancer risk independently from known risk factors. Future research should focus on biologic mechanisms underlying this association.
Impact:
This study provides evidence that hypertension may be an independent risk factor for endometrial cancer.
Supplementary Table S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Authors: Brugarolas James , Obara Gregory , Beckermann Kathryn E. , Rini Brian , Lam Elaine T. , Hamilton James , Schluep Thomas , Yi Min , Wong So , Mao Zhongping Lily , Gamelin Erick , Tannir Nizar M.
Published: June 2024

Table S6: Summary of Treatment Exposure (Safety Analysis Set)
Supplementary Table S1 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Authors: Magbanua Mark Jesus M. , Ahmed Ziad , Sayaman Rosalyn W. , Brown Swigart Lamorna , Hirst Gillian L. , Yau Christina , Wolf Denise M. , Li Wen , Delson Amy L. , Perlmutter Jane , Pohlmann Paula , Symmans W. Fraser , Yee Douglas , Hylton Nola M. , Esserman Laura J. , DeMichele Angela M. , Rugo Hope S. , van 't Veer Laura J.
Published: June 2024

Representativeness of Study Participants
Supplementary Table S3 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Authors: Brugarolas James , Obara Gregory , Beckermann Kathryn E. , Rini Brian , Lam Elaine T. , Hamilton James , Schluep Thomas , Yi Min , Wong So , Mao Zhongping Lily , Gamelin Erick , Tannir Nizar M.
Published: June 2024

Table S3: Comparison of ARO-HIF2 Plasma Exposures Following the First and the Third Weekly Dose
Supplementary Figure S3 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Authors: Magbanua Mark Jesus M. , Ahmed Ziad , Sayaman Rosalyn W. , Brown Swigart Lamorna , Hirst Gillian L. , Yau Christina , Wolf Denise M. , Li Wen , Delson Amy L. , Perlmutter Jane , Pohlmann Paula , Symmans W. Fraser , Yee Douglas , Hylton Nola M. , Esserman Laura J. , DeMichele Angela M. , Rugo Hope S. , van 't Veer Laura J.
Published: June 2024

Association between pretreatment cfDNA concentration and clinicopathologic variables. CfDNA concentration was measured in pretreatment plasma of patients with A. hormone receptor-positive HER2-negative (HR+HER2-) and B. triple-negative breast cancers (TNBC). P values were calculated using the Wilcoxon rank sum test.
Supplemental Figure 8 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Authors: Ciccone Roselia , Quintarelli Concetta , Camera Antonio , Pezzella Michele , Caruso Simona , Manni Simona , Ottaviani Alessio , Guercio Marika , Del Bufalo Francesca , Quadraccia Maria Cecilia , Orlando Domenico , Di Cecca Stefano , Sinibaldi Matilde , Aurigemma Mariasole , Iaffaldano Laura , Sarcinelli Andrea , D'Amore Maria Luisa , Ceccarelli Manuela , Nazio Francesca , Marabitti Veronica , Giorda Ezio , Pezzullo Marco , De Stefanis Cristiano , Carai Andrea , Rossi Sabrina , Alaggio Rita , Del Baldo Giada , Becilli Marco , Mastronuzzi Angela , De Angelis Biagio , Locatelli Franco
Published: June 2024

Supplemental Figure 8. Tazemetostat did not modulate GD2 expression in normal cells.
Supplementary Video S3 from A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer
Authors: Zanoni Daniella K. , Demétrio De Souza França Paula , Valero Cristina , Peterson Gary , Ardigo Marco , Ghossein Ronald , Dusza Stephen W. , Matsuura Danielli , Scholfield Daniel W. , Adilbay Dauren , Montero Pablo H. , Migliacci Jocelyn , Pillarsetty Naga Vara Kishore , Kose Kivanc , Ganly Ian , Rajadhyaksha Milind , Patel Snehal G.
Published: June 2024

Supplementary Video S3 shows an example of normal tissue. Normal tissue consists of cells arranged in an organized manner.
Supplemental Figure 2 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Authors: Ciccone Roselia , Quintarelli Concetta , Camera Antonio , Pezzella Michele , Caruso Simona , Manni Simona , Ottaviani Alessio , Guercio Marika , Del Bufalo Francesca , Quadraccia Maria Cecilia , Orlando Domenico , Di Cecca Stefano , Sinibaldi Matilde , Aurigemma Mariasole , Iaffaldano Laura , Sarcinelli Andrea , D'Amore Maria Luisa , Ceccarelli Manuela , Nazio Francesca , Marabitti Veronica , Giorda Ezio , Pezzullo Marco , De Stefanis Cristiano , Carai Andrea , Rossi Sabrina , Alaggio Rita , Del Baldo Giada , Becilli Marco , Mastronuzzi Angela , De Angelis Biagio , Locatelli Franco
Published: June 2024

Supplemental Figure 2. GD2 evaluation in MB cell lines.
Supplementary Figure S7 from A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer
Authors: Zanoni Daniella K. , Demétrio De Souza França Paula , Valero Cristina , Peterson Gary , Ardigo Marco , Ghossein Ronald , Dusza Stephen W. , Matsuura Danielli , Scholfield Daniel W. , Adilbay Dauren , Montero Pablo H. , Migliacci Jocelyn , Pillarsetty Naga Vara Kishore , Kose Kivanc , Ganly Ian , Rajadhyaksha Milind , Patel Snehal G.
Published: June 2024

Supplementary Figure S7 shows in vivo RCM images of a tumor area in a 75-year-old male, with a history of 30 packs/year of cigarette exposure and no history of alcohol use, harboring an exophytic 2 cm right lateral tongue moderately differentiated oral squamous cell carcinoma.
Supplementary Figure S3 from A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer
Authors: Zanoni Daniella K. , Demétrio De Souza França Paula , Valero Cristina , Peterson Gary , Ardigo Marco , Ghossein Ronald , Dusza Stephen W. , Matsuura Danielli , Scholfield Daniel W. , Adilbay Dauren , Montero Pablo H. , Migliacci Jocelyn , Pillarsetty Naga Vara Kishore , Kose Kivanc , Ganly Ian , Rajadhyaksha Milind , Patel Snehal G.
Published: June 2024

Supplementary Figure S3 shows in vivo RCM images of a tumor area in a 74-year-old male, with 35 packs/years of smoking history and daily alcohol exposure. The patient harbored a leukoplastic lesion on the upper gingiva.
Supplementary Figure S3 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Authors: Moyer Cassandra L. , Lanier Amanda , Qian Jing , Coleman Darian , Hill Jamal , Vuligonda Vidyasagar , Sanders Martin E. , Mazumdar Abhijit , Brown Powel H.
Published: June 2024

Supplementary figure with representative cell cycle progression
Supplementary Table 6 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

Clinical table of PDAC patients who underwent longitudinal collection of PBMCS for single cell RNA sequencing
Supplementary Fig 12 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

CXCL8 levels in patient plasma correlate with abundance of KRT17high; CXCL8+ cancer cells in neoadjuvant-treated patients.
Supplementary Figure S6 from Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Authors: Jamieson Amy , Sobral de Barros Juliana , Cochrane Dawn R. , Douglas J. Maxwell , Shankar Sameer , Lynch Branden J. , Leung Samuel , Martin Spencer , Senz Janine , Lum Amy , Drew Yvette , Gilks C. Blake , Huntsman David G. , McAlpine Jessica N.
Published: June 2024

Supplemental Figure 6. Pearson’s correlation between signature exposures to the Vancouver (A) or BriTROC (B) signatures and the predicted probability of chromothripsis according to GECNVNet. P-values were adjusted for multiple comparisons via Holm-Bonferroni.
Supplementary Figure 4 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Chen Junru , Hu Xu , Zhao Junjie , Yin Xiaoxue , Zheng Linmao , Guo Jingjing , Chen Jianhui , Wang Yongquan , Sheng Xinan , Dong Haiying , Liu Xiaodong , Zhang Xingming , Liang Jiayu , Liu Haolin , Yao Jin , Liu Jiyan , Shen Yali , Chen Zhibin , He Zhengyu , Wang Yaodong , Chen Ni , Nie Ling , Zhang Mengni , Pan Xiuyi , Chen Yuntian , Liu Haoyang , Zhang Yaowen , Tang Yanfeng , Zhu Sha , Zhao Jinge , Dai Jindong , Wang Zilin , Zeng Yuhao , Wang Zhipeng , Huang Haojie , Liu Zhenhua , Shen Pengfei , Zeng Hao , Sun Guangxi
Published: June 2024

Supplementary Figure 4. Cell clusters in FH-deficient RCC stratified by immunotherapeutic response. (A) UMAP plot showing 23 cellclusters in FH-deficient RCC; (B) Bar plots showing tissue distribution of the eight main cell clusters using our data; (C) UMAP plot showing the tissue distribution of T cells using our data; (D) Quantification of T cell cluster frequency between responders and non-responders using bulk RNA-seq data after deconvolution, significance of differential signature expression (q value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction.*, q<0.05; **, q<0.01; ***, q<0.001; NS, not significant.
Supplementary Table S2 from Stabilizing Tumor-Resident Mast Cells Restores T-Cell Infiltration and Sensitizes Sarcomas to PD-L1 Inhibition
Authors: Panagi Myrofora , Mpekris Fotios , Voutouri Chrysovalantis , Hadjigeorgiou Andreas G. , Symeonidou Chloe , Porfyriou Eleni , Michael Christina , Stylianou Andreas , Martin John D. , Cabral Horacio , Constantinidou Anastasia , Stylianopoulos Triantafyllos
Published: June 2024

ANOVA test for the coefficients of the model. P-values less than 0.05 indicate that the coefficients of the model are significantly different than zero.
Supplementary Figure 1 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Chen Junru , Hu Xu , Zhao Junjie , Yin Xiaoxue , Zheng Linmao , Guo Jingjing , Chen Jianhui , Wang Yongquan , Sheng Xinan , Dong Haiying , Liu Xiaodong , Zhang Xingming , Liang Jiayu , Liu Haolin , Yao Jin , Liu Jiyan , Shen Yali , Chen Zhibin , He Zhengyu , Wang Yaodong , Chen Ni , Nie Ling , Zhang Mengni , Pan Xiuyi , Chen Yuntian , Liu Haoyang , Zhang Yaowen , Tang Yanfeng , Zhu Sha , Zhao Jinge , Dai Jindong , Wang Zilin , Zeng Yuhao , Wang Zhipeng , Huang Haojie , Liu Zhenhua , Shen Pengfei , Zeng Hao , Sun Guangxi
Published: June 2024

Supplementary Figure 1. Survival outcomes of patients with synchronous and metachronous metastatic disease and treatment flows. Overall survival (OS) for patients with synchronous and metachronous metastatic FH-deficient RCC in the overall systemic treatment setting (A), ICI+TKI treatment setting (B), and TKI monotherapy setting (C); (D) Sankey diagram showing systemic treatment flows in patients with metastatic FH-deficient RCC.
Supplementary Figure S4 from Stabilizing Tumor-Resident Mast Cells Restores T-Cell Infiltration and Sensitizes Sarcomas to PD-L1 Inhibition
Authors: Panagi Myrofora , Mpekris Fotios , Voutouri Chrysovalantis , Hadjigeorgiou Andreas G. , Symeonidou Chloe , Porfyriou Eleni , Michael Christina , Stylianou Andreas , Martin John D. , Cabral Horacio , Constantinidou Anastasia , Stylianopoulos Triantafyllos
Published: June 2024

10 mg/kg ketotifen dose is tolerable.
Supplementary Figure S8 from Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk
Authors: Silver Alexander J. , Vlasschaert Caitlyn , Mack Taralynn , Sharber Brian , Xu Yaomin , Bick Alexander G. , Pinson C. Wright , Savona Michael R.
Published: June 2024

Supplementary Figure S8. Distribution of allograft complications in the UK Biobank.
Supplementary Figure S6 from Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk
Authors: Silver Alexander J. , Vlasschaert Caitlyn , Mack Taralynn , Sharber Brian , Xu Yaomin , Bick Alexander G. , Pinson C. Wright , Savona Michael R.
Published: June 2024

Supplementary Figure S6. CHIP mutation abundance and VAF as a function of time since transplantation for the All of Us cohort.
Supplementary Figure S1 from Stabilizing Tumor-Resident Mast Cells Restores T-Cell Infiltration and Sensitizes Sarcomas to PD-L1 Inhibition
Authors: Panagi Myrofora , Mpekris Fotios , Voutouri Chrysovalantis , Hadjigeorgiou Andreas G. , Symeonidou Chloe , Porfyriou Eleni , Michael Christina , Stylianou Andreas , Martin John D. , Cabral Horacio , Constantinidou Anastasia , Stylianopoulos Triantafyllos
Published: June 2024

In vitro interaction between mast cells and cancer-associated fibroblasts.
Supplementary Table S5 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Table 5. Full list of serum metabolites analysed.
Supplementary Table S1 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Authors: Iwase Toshiaki , Cohen Evan N. , Gao Hui , Alexander Angela , Kai Megumi , Chiv Vivian , Wang Xiaoping , Krishnamurthy Savitri , Liu Diane , Shen Yu , Kida Kumiko , Reuben Alexandre , Layman Rachel M. , Ramirez David L. , Tripathy Debasish , Moulder Stacy L. , Yam Clinton , Valero Vicente , Lim Bora , Reuben James M. , Ueno Naoto T.
Published: June 2024

Representativeness of Study Participants
Supplementary Figure S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Figure S8.
The Variant Allele Frequency (VAF) of specific mutations changes during the course of the treatment. For instance, the VAF of ARID1a increases at treatment failure in patients 025 and 022 (both responders, Panel A). Furthermore, within the same patient, the VAF of different mutations changes coherently with the course of the treatment, as showed for patient 022 (B) and 002 (C), where the VAF increases at treatment discontinuation. Abbreviation: EOT, end of treatment.
Supplementary Figure S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
Authors: Iwase Toshiaki , Cohen Evan N. , Gao Hui , Alexander Angela , Kai Megumi , Chiv Vivian , Wang Xiaoping , Krishnamurthy Savitri , Liu Diane , Shen Yu , Kida Kumiko , Reuben Alexandre , Layman Rachel M. , Ramirez David L. , Tripathy Debasish , Moulder Stacy L. , Yam Clinton , Valero Vicente , Lim Bora , Reuben James M. , Ueno Naoto T.
Published: June 2024

Supplementary Figure 2. Overall survival duration by tumor type.
Supplementary Figure 1 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Authors: Rolfo Christian D. , Madison Russell W. , Pasquina Lincoln W. , Brown Derek W. , Huang Yanmei , Hughes Jason D. , Graf Ryon P. , Oxnard Geoffrey R. , Husain Hatim
Published: June 2024

Supplementary Figure 1: Paired tissue and liquid biopsy specimens were used to assess sensitivity (PPA), negative predictive value (NPV), and specificity (NPA) for detection of driver alterations in multiple cancer types.
Data from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Authors: Ciccone Roselia , Quintarelli Concetta , Camera Antonio , Pezzella Michele , Caruso Simona , Manni Simona , Ottaviani Alessio , Guercio Marika , Del Bufalo Francesca , Quadraccia Maria Cecilia , Orlando Domenico , Di Cecca Stefano , Sinibaldi Matilde , Aurigemma Mariasole , Iaffaldano Laura , Sarcinelli Andrea , D'Amore Maria Luisa , Ceccarelli Manuela , Nazio Francesca , Marabitti Veronica , Giorda Ezio , Pezzullo Marco , De Stefanis Cristiano , Carai Andrea , Rossi Sabrina , Alaggio Rita , Del Baldo Giada , Becilli Marco , Mastronuzzi Angela , De Angelis Biagio , Locatelli Franco
Published: June 2024

AbstractPurpose:
Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor (CAR) T cells directed toward the disialoganglioside GD2 can represent a potentially more effective treatment with reduced long-term side effects.
Experimental Design:
GD2 expression was evaluated on primary tumor biopsies of MB children by flow cytometry. GD2 expression in MB cells was also evaluated in response to an EZH2 inhibitor (tazemetostat). In in vitro and in vivo models, GD2+ MB cells were targeted by a CAR-GD2.CD28.4-1BBζ (CAR.GD2)-T construct, including the suicide gene inducible caspase-9.
Results:
GD2 was expressed in 82.68% of MB tumors. The SHH and G3–G4 subtypes expressed the highest levels of GD2, whereas the WNT subtype expressed the lowest. In in vitro coculture assays, CAR.GD2 T cells were able to kill GD2+ MB cells. Pretreatment with tazemetostat upregulated GD2 expression, sensitizing GD2dimMB cells to CAR.GD2 T cells cytotoxic activity. In orthotopic mouse models of MB, intravenously injected CAR.GD2 T cells significantly controlled tumor growth, prolonging the overall survival of treated mice. Moreover, the dimerizing drug AP1903 was able to cross the murine blood–brain barrier and to eliminate both blood-circulating and tumor-infiltrating CAR.GD2 T cells.
Conclusions:
Our experimental data indicate the potential efficacy of CAR.GD2 T-cell therapy. A phase I/II clinical trial is ongoing in our center (NCT05298995) to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.
Data from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer
Authors: Han Yoo Jane , Liu Siyao , Hardeman Ashley , Rajagopal Padma Sheila , Mueller Jeffrey , Khramtsova Galina , Sanni Ayodele , Ajani Mustapha , Clayton Wendy , Hurley Ian W. , Yoshimatsu Toshio F. , Zheng Yonglan , Parker Joel , Perou Charles M. , Olopade Olufunmilayo I.
Published: June 2024

AbstractPurpose:
Black women experience the highest breast cancer mortality rate compared with women of other racial/ethnic groups. To gain a deeper understanding of breast cancer heterogeneity across diverse populations, we examined a VEGF-hypoxia gene expression signature in breast tumors from women of diverse ancestry.
Experimental Design:
We developed a NanoString nCounter gene expression panel and applied it to breast tumors from Nigeria (n = 182) and the University of Chicago (Chicago, IL; n = 161). We also analyzed RNA sequencing data from Nigeria (n = 84) and The Cancer Genome Atlas (TCGA) datasets (n = 863). Patient prognosis was analyzed using multiple datasets.
Results:
The VEGF-hypoxia signature was highest in the basal-like subtype compared with other subtypes, with greater expression in Black women compared with White women. In TCGA dataset, necrotic breast tumors had higher scores for the VEGF-hypoxia signature compared with non-necrosis tumors (P < 0.001), with the highest proportion in the basal-like subtype. Furthermore, necrotic breast tumors have higher scores for the proliferation signature, suggesting an interaction between the VEGF-hypoxia signature, proliferation, and necrosis. T-cell gene expression signatures also correlated with the VEGF-hypoxia signature when testing all tumors in TCGA dataset. Finally, we found a significant association of the VEGF-hypoxia profile with poor outcomes when using all patients in the METABRIC (P < 0.0001) and SCAN-B datasets (P = 0.002).
Conclusions:
These data provide further evidence for breast cancer heterogeneity across diverse populations and molecular subtypes. Interventions selectively targeting VEGF-hypoxia and the immune microenvironment have the potential to improve overall survival in aggressive breast cancers that disproportionately impact Black women in the African Diaspora.
Data from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Chen Junru , Hu Xu , Zhao Junjie , Yin Xiaoxue , Zheng Linmao , Guo Jingjing , Chen Jianhui , Wang Yongquan , Sheng Xinan , Dong Haiying , Liu Xiaodong , Zhang Xingming , Liang Jiayu , Liu Haolin , Yao Jin , Liu Jiyan , Shen Yali , Chen Zhibin , He Zhengyu , Wang Yaodong , Chen Ni , Nie Ling , Zhang Mengni , Pan Xiuyi , Chen Yuntian , Liu Haoyang , Zhang Yaowen , Tang Yanfeng , Zhu Sha , Zhao Jinge , Dai Jindong , Wang Zilin , Zeng Yuhao , Wang Zhipeng , Huang Haojie , Liu Zhenhua , Shen Pengfei , Zeng Hao , Sun Guangxi
Published: June 2024

AbstractPurpose:
Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare and lethal subtype of kidney cancer. However, the optimal treatments and molecular correlates of benefits for FH-deficient RCC are currently lacking.
Experimental Design:
A total of 91 patients with FH-deficient RCC from 15 medical centers between 2009 and 2022 were enrolled in this study. Genomic and bulk RNA-sequencing (RNA-seq) were performed on 88 and 45 untreated FH-deficient RCCs, respectively. Single-cell RNA-seq was performed to identify biomarkers for treatment response. Main outcomes included disease-free survival (DFS) for localized patients, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) for patients with metastasis.
Results:
In the localized setting, we found that a cell-cycle progression signature enabled to predict disease progression. In the metastatic setting, first-line immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI+TKI) combination therapy showed satisfactory safety and was associated with a higher ORR (43.2% vs. 5.6%), apparently superior PFS (median PFS, 17.3 vs. 9.6 months, P = 0.016) and OS (median OS, not reached vs. 25.7 months, P = 0.005) over TKI monotherapy. Bulk and single-cell RNA-seq data revealed an enrichment of memory and effect T cells in responders to ICI plus TKI combination therapy. Furthermore, we identified a signature of memory and effect T cells that was associated with the effectiveness of ICI plus TKI combination therapy.
Conclusions:
ICI plus TKI combination therapy may represent a promising treatment option for metastatic FH-deficient RCC. A memory/active T-cell–derived signature is associated with the efficacy of ICI+TKI but necessitates further validation.
Data from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Authors: Liu Jiangang , Moura David S. , Jones Robin L. , Aggarwal Amit , Ebert Philip J. , Wagner Andrew J. , Wright Jennifer , Martin-Broto Javier , Tap William D.
Published: June 2024

AbstractPurpose:
This exploratory analysis evaluated the tumor samples of the patients treated with doxorubicin (with or without olaratumab) in a negative phase III ANNOUNCE trial to better understand the complexity of advanced soft tissue sarcomas (STS) and to potentially identify its predictive markers.
Experimental Design:
RNA sequencing was performed on pretreatment tumor samples (n = 273) from the ANNOUNCE trial to evaluate response patterns and identify potential predictive treatment markers for doxorubicin. A BOR-associated signature to doxorubicin (REDSARC) was created by evaluating tumors with radiographic response versus progression. An external cohort of doxorubicin-treated patients from the Spanish Group for Research on Sarcomas (GEIS) was used for refinement and validation.
Results:
A total of 259 samples from the trial were considered for analysis. Comparative analyses by the treatment arm did not explain the negative trial. However, there was an association between the BOR signature and histologic subtype (χ2P = 2.0e−7) and grade (P = 0.002). There were no associations between the BOR signature and gender, age, ethnicity, or stage. Applied to survival outcomes, REDSARC was also predictive for progression-free survival (PFS) and overall survival (OS). Using the GEIS cohort, a refined 25-gene signature was identified and applied to the ANNOUNCE cohort, where it was predictive of PFS and OS in leiomyosarcoma, liposarcoma, and other sarcoma subtypes, but not in undifferentiated pleomorphic sarcoma.
Conclusions:
The refined REDSARC signature provides a potential tool to direct the application of doxorubicin in sarcomas and other malignancies. Validation and further refinement of the signature in other potentially subtype specific prospective cohorts is recommended.
TRACERx Consortium Members from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Authors: Enfield Katey S.S. , Colliver Emma , Lee Claudia , Magness Alastair , Moore David A. , Sivakumar Monica , Grigoriadis Kristiana , Pich Oriol , Karasaki Takahiro , Hobson Philip S. , Levi Dina , Veeriah Selvaraju , Puttick Clare , Nye Emma L. , Green Mary , Dijkstra Krijn K. , Shimato Masako , Akarca Ayse U. , Marafioti Teresa , Salgado Roberto , Hackshaw Allan , Jamal-Hanjani Mariam , van Maldegem Febe , McGranahan Nicholas , Glass Benjamin , Pulaski Hanna , Walk Eric , Reading James L. , Quezada Sergio A. , Hiley Crispin T. , Downward Julian , Sahai Erik , Swanton Charles , Angelova Mihaela
Published: June 2024

All consortium members and their affiliations.
Figure 2 from Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Authors: Enfield Katey S.S. , Colliver Emma , Lee Claudia , Magness Alastair , Moore David A. , Sivakumar Monica , Grigoriadis Kristiana , Pich Oriol , Karasaki Takahiro , Hobson Philip S. , Levi Dina , Veeriah Selvaraju , Puttick Clare , Nye Emma L. , Green Mary , Dijkstra Krijn K. , Shimato Masako , Akarca Ayse U. , Marafioti Teresa , Salgado Roberto , Hackshaw Allan , Jamal-Hanjani Mariam , van Maldegem Febe , McGranahan Nicholas , Glass Benjamin , Pulaski Hanna , Walk Eric , Reading James L. , Quezada Sergio A. , Hiley Crispin T. , Downward Julian , Sahai Erik , Swanton Charles , Angelova Mihaela
Published: June 2024

Four TME classes in NSCLC defined by immune composition in tumor nests and surrounding stroma. A, Tumor cores were classified into four TME classes, derived by clustering immune cell densities in the tumor nest and stroma. Only LUAD (n = 65 cores, 35 tumors) and LUSC (n = 48, 23 tumors) tumor cores are featured, and corresponding clinical annotations are displayed. Regional growth patterns are shown for LUAD: lepidic (low grade), acinar and papillary (mid-grade), solid and cribriform (high grade). B, TME classifications displayed separately for LUAD and LUSC. Numbers indicate the number of cores with a given TME class for each histology subtype. The barplot shows the total expressed neoantigen count for all predicted HLA alleles in the range 0–269 for LUAD and 23–160 for LUSC, colored by their clonal and subclonal status. Horizontal lines connect tumor cores from the same multiregion tumor (n = 33 tumors). The annotation bars display tumor genomic features and PD-L1 tumor cell (TC) staining (SP142 IHC) for the corresponding tumor cores. C, Composite images and cell type maps of representative examples for each TME class. Crop insets are 82 μm in diameter. D, A heat map of T values derived from an LMEM of the major cell type density across TME classes, adjusted for histology subtype as a fixed effect and patient as a random effect. Significant relationships are indicated with an asterisk for P ≤ 0.05. TIL, tumor-infiltrating lymphocyte; MΦ, macrophage; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NSCLC, non–small cell lung cancer; TME, tumor microenvironment; TMB, tumor mutation burden; muts/Mb, mutations per megabase; panCK, pancytokeratin; LMEM, linear mixed effects model.
Supplementary Figure 2 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Authors: Stutheit-Zhao Eric Y. , Sanz-Garcia Enrique , Liu Zhihui (Amy) , Wong Derek , Marsh Kayla , Abdul Razak Albiruni R. , Spreafico Anna , Bedard Philippe L. , Hansen Aaron R. , Lheureux Stephanie , Torti Dax , Lam Bernard , Yang Shih Yu Cindy , Burgener Justin , Luo Ping , Zeng Yong , Cheng Nicholas , Awadalla Philip , Bratman Scott V. , Ohashi Pamela S. , Pugh Trevor J. , Siu Lillian L.
Published: June 2024

Overall survival (OS) and progression free survival (PFS) in included patients by cohort. (A) Kaplan-meier curves are shown indicating the OS and PFS of patients in five histology-specific cohorts. (B) Forest plot of the hazard ratios for each cohort in a Cox proportional hazards model, with Cohort A as the reference level.
Supplementary_Table_S2 from Glioblastoma-Infiltrating CD8+ T Cells Are Predominantly a Clonally Expanded GZMK+ Effector Population
Authors: Wang Anthony Z. , Mashimo Bryce L. , Schaettler Maximilian O. , Sherpa Ngima D. , Leavitt Lydia A. , Livingstone Alexandra J. , Khan Saad M. , Li Mao , Anzaldua-Campos Markus I. , Bradley Joseph D. , Leuthardt Eric C. , Kim Albert H. , Dowling Joshua L. , Chicoine Michael R. , Jones Pamela S. , Choi Bryan D. , Cahill Daniel P. , Carter Bob S. , Petti Allegra A. , Johanns Tanner M. , Dunn Gavin P.
Published: June 2024

Gene markers for cell type identification and gene signatures.
Supplementary Table 8 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers
Authors: Liu Zhenyu , Hu Yuqiong , Xie Haoling , Chen Kexuan , Wen Lu , Fu Wei , Zhou Xin , Tang Fuchou
Published: June 2024

Supplementary Table 8. Motif enrichment in marker peaks of CIMP-High, CIMP-Low, and CIMP-Negative tumors.
Supplementary Table 5 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers
Authors: Liu Zhenyu , Hu Yuqiong , Xie Haoling , Chen Kexuan , Wen Lu , Fu Wei , Zhou Xin , Tang Fuchou
Published: June 2024

Supplementary Table 5. Motif enrichment results of iCMS2-specific, iCMS3-specific, and iCMS2&3 shared peaks.
Supplementary Table 1 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers
Authors: Liu Zhenyu , Hu Yuqiong , Xie Haoling , Chen Kexuan , Wen Lu , Fu Wei , Zhou Xin , Tang Fuchou
Published: June 2024

Supplementary Table 1. Clinical information of CRC cohort.
Supplementary Figure 4 from Single-Cell Chromatin Accessibility Analysis Reveals the Epigenetic Basis and Signature Transcription Factors for the Molecular Subtypes of Colorectal Cancers
Authors: Liu Zhenyu , Hu Yuqiong , Xie Haoling , Chen Kexuan , Wen Lu , Fu Wei , Zhou Xin , Tang Fuchou
Published: June 2024

Supplementary Figure 4. Dynamics of gene expression along malignant transformation.
Data from Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
Authors: Yaeger Rona , Uboha Nataliya V. , Pelster Meredith S. , Bekaii-Saab Tanios S. , Barve Minal , Saltzman Joel , Sabari Joshua K. , Peguero Julio A. , Paulson Andrew Scott , Jänne Pasi A. , Cruz-Correa Marcia , Anderes Kenna , Velastegui Karen , Yan Xiaohong , Der-Torossian Hirak , Klempner Samuel J. , Kopetz Scott E.
Published: June 2024

Abstract
Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance.
Significance:
Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer.

This article is featured in Selected Articles from This Issue, p. 897

See co-corresponding author Rona Yaeger discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606282/f27a6e46f4
Data from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Authors: Stutheit-Zhao Eric Y. , Sanz-Garcia Enrique , Liu Zhihui (Amy) , Wong Derek , Marsh Kayla , Abdul Razak Albiruni R. , Spreafico Anna , Bedard Philippe L. , Hansen Aaron R. , Lheureux Stephanie , Torti Dax , Lam Bernard , Yang Shih Yu Cindy , Burgener Justin , Luo Ping , Zeng Yong , Cheng Nicholas , Awadalla Philip , Bratman Scott V. , Ohashi Pamela S. , Pugh Trevor J. , Siu Lillian L.
Published: June 2024

Abstract
Early kinetics of circulating tumor DNA (ctDNA) in plasma predict response to pembrolizumab but typically requires sequencing of matched tumor tissue or fixed gene panels. We analyzed genome-wide methylation and fragment-length profiles using cell-free methylated DNA immunoprecipitation and sequencing (cfMeDIP-seq) in 204 plasma samples from 87 patients before and during treatment with pembrolizumab from a pan-cancer phase II investigator-initiated trial (INSPIRE). We trained a pan-cancer methylation signature using independent methylation array data from The Cancer Genome Atlas to quantify cancer-specific methylation (CSM) and fragment-length score (FLS) for each sample. CSM and FLS are strongly correlated with tumor-informed ctDNA levels. Early kinetics of CSM predict overall survival and progression-free survival, independently of tumor type, PD-L1, and tumor mutation burden. Early kinetics of FLS are associated with overall survival independently of CSM. Our tumor-naïve mutation-agnostic ctDNA approach integrating methylomics and fragmentomics could predict outcomes in patients treated with pembrolizumab.
Significance:
Analysis of methylation and fragment length in plasma using cfMeDIP-seq provides a tumor-naive approach to measure ctDNA with results comparable with a tumor-informed bespoke ctDNA. Early kinetics within the first weeks of treatment in methylation and fragment quantity can predict outcomes with pembrolizumab in patients with various advanced solid tumors.

This article is featured in Selected Articles from This Issue, p. 897
When Lightning Strikes Twice: Routes to Second Malignancies in Young Patients
Authors: Pacyna Clarissa N. , Nangalia Jyoti
Published: June 2024

Given the rarity of cancer in childhood, it should be even more uncommon for pediatric cancer survivors to develop a second, independent malignancy, yet they incur a greatly elevated risk after initial remission. In this issue of Cancer Discovery, Sánchez-Guixé and colleagues unpick the origins of second tumours in four children, and the potential role platinum-based chemotherapy may play in subsequent tumorigenesis.

See related article by Sánchez-Guixé et al., p. 953 (8).
Optimus-Era Dose Finding for Rare Cancers
Authors: Murciano-Goroff Yonina R. , Devlin Sean M. , Iasonos Alexia , Drilon Alexander
Published: June 2024

Advances in cancer biology and diagnostics have led to the recognition of a multitude of rare cancer subtypes, emphasizing the pressing need for strategies to accelerate drug development for patients with these cancers. This paper addresses the unique challenges of dose finding in trials that accrue small numbers of patients with rare cancers; strategies for dose optimization are proposed, in line with evolving approaches to dose determination in the age of the US Food and Drug Administration's Project Optimus.
Supplementary Figure S6 from Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer
Authors: Rustgi Naryan , Wu Sharon , Samec Timothy , Walker Phillip , Xiu Joanne , Lou Emil , Goel Sanjay , Saeed Anwaar , Moy Ryan H.
Published: June 2024

Supplementary Figure S6 shows differential gene expression analysis of CCNE1-amplified vs non-amplified EGC
Supplementary Figure S4 from Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer
Authors: Rustgi Naryan , Wu Sharon , Samec Timothy , Walker Phillip , Xiu Joanne , Lou Emil , Goel Sanjay , Saeed Anwaar , Moy Ryan H.
Published: June 2024

Supplementary Figure S4 shows co-altered genes with CCNE1 amplification from an EGC MSK-IMPACT sequencing cohort
FIGURE 4 from Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer
Authors: Rustgi Naryan , Wu Sharon , Samec Timothy , Walker Phillip , Xiu Joanne , Lou Emil , Goel Sanjay , Saeed Anwaar , Moy Ryan H.
Published: June 2024

rwOS in patients with CCNE1-amplified gastric adenocarcinoma. OS (calculated from tissue collection to last day of contact) of CCNE1-amplified versus nonamplified gastric adenocarcinoma (A). Comparison of survival of CCNE1-amplified versus nonamplified gastric adenocarcinoma treated with oxaliplatin (calculated from start of treatment to last day of contact; B). Comparison of survival of CCNE1-amplified versus nonamplified gastric adenocarcinoma treated with trastuzumab (C). Comparison of survival of CCNE1-amplified versus nonamplified HER2-positive gastric adenocarcinoma (by IHC) treated with trastuzumab (D). Comparison of survival of CCNE1-amplified versus nonamplified HER2-positive gastric adenocarcinoma (by ERBB2 CNA analysis) treated with trastuzumab (E). Comparison of survival of CCNE1-amplified versus nonamplified gastric adenocarcinoma treated with immunotherapy with a PD1 or PD-L1 inhibitor (F).